Patients Withdrawing Dupilumab Monotherapy for COVID-19–Related Reasons Showed Similar Disease Course Compared with Patients Continuing Dupilumab Therapy

Abstract

Get full access to this article

View all access options for this article.

References

Stingeni

, Hansel

, Antonelli

, et al. Atopic dermatitis in adolescents: effectiveness and safety of dupilumab in a 16-week real-life experience during the COVID-19 pandemic in Italy. Dermatol Ther. 2021; 34:e15035. . Epub ahead of print.

Rossi

, Rovati

, Arisi

, et al. Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID-19 pandemic: a single-center real-life experience. Dermatol Ther, 2020; 33(4):e13765.

Chiricozzi

, Talamonti

, De Simone

, et alDA-COVID-19 study group. Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: data from the DA-COVID-19 registry. Allergy, 2021; 76(6):1813–1824.

Gori

, Chiricozzi

, Malvaso

, et al. Successful combination of systemic agents for the treatment of atopic dermatitis resistant to dupilumab therapy. Dermatology, 2021; 237(4):535–541.

Deleuran

, Thaçi

, Beck

, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol, 2020; 82(2):377–388.